RTA 408: Phase II start

Next month, Reata will begin a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate 2.5, 5 and 10 mg oral RTA 408 once daily for 12 weeks in about 52 patients with mitoch...